Clinical outcomes of MTC patients with other mutations in the extracellular CRD of RET enrolled to the LIBRETTO-001 study suggest that this receptor with a 6-base pair in-frame deletion responds to RET kinase inhibition in a manner similar to cysteine substitutions and other deletions and insertions in the CRD. This evidence concerns the gene RET and medullary thyroid gland carcinoma.